{"id":2641,"date":"2018-05-11T17:36:16","date_gmt":"2018-05-11T12:06:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2641"},"modified":"2023-08-17T10:55:50","modified_gmt":"2023-08-17T05:25:50","slug":"hematopoietic-stem-cells-transplantation","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation","title":{"rendered":"Hematopoietic Stem Cell Transplantation"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/hematopoietic-stem-cell-transplantation-market\">Hematopoietic stem cells (HSCs)<\/a>\u00a0are characterized by the ability to self-renew and differentiate into all mature blood lineages. Stromal interactions with soluble and cell-bound cytokines structures the differentiations and proliferation of hematopoietic cells.<\/p>\n<p style=\"text-align: justify;\">Hematopoietic stem cell transplantation (HSCT) is the <strong>intravenous infusion<\/strong> of hematopoietic stem and progenitor cells intended to establish marrow and immune function in patients with a variety of acquired and inherited malignant and non-malignant disorders. <strong>Allogeneic and Autologous<\/strong> are the two <strong>types<\/strong> of HSCTS wherein a suitable donor is vital to source the apt stem cells for Allogeneic HSCT. The source of autologous transplantation is usually peripheral blood stem cells, mobilized with granulocyte colony-stimulating factor (GCSF) sometimes following salvage\/priming chemotherapy.<\/p>\n<p style=\"text-align: justify;\"><strong>Bone Marrow<\/strong> and <strong>Peripheral Blood<\/strong> are the two major sites for the collection of the hematopoietic stem cells in addition to the <strong>Umbilical Cord<\/strong>.<\/p>\n<p style=\"text-align: justify;\">HSCT can be <strong>brought into effect<\/strong> for patients with marrow involvement by tumor or with bone marrow dysfunction. It holds a great promise for the <strong>development of the regenerative medicines<\/strong>. HSCT is the only <strong>potentially<\/strong> curative treatment for patients with <strong>chemotherapy-resistant hematological malignancies<\/strong>, which are usually fatal in the absence of treatment. Intensive conditioning regimens, effective GVHD prophylaxis, cyclosporine-based regimens, and improved supportive care (eg, antibiotics as needed, herpesvirus and cytomegalovirus prophylaxis) have <strong>increased long-term disease-free survival <\/strong>after HSC transplantation.<\/p>\n<p style=\"text-align: justify;\">There is even the other part of the story which throws some amount of light on the <strong>complications<\/strong> of HSCT despite of wide range of therapeutic benefits of the therapy. The high chemotherapy doses used in HSCT cause significant <strong>drug toxicities<\/strong>, <strong>graft-versus-host-disease<\/strong> (GVHD) and other complications from prolonged immunodeficiency and require an extended recovery process.<\/p>\n<p style=\"text-align: justify;\">Currently, there are <strong>no marketed drugs<\/strong> for HSCT. The therapies available in the market deals with the decline in the complications observed after HSCT. Moreover, the pipeline for HSCT is not very robust and includes only <strong>5 pipeline products<\/strong>.<\/p>\n<p style=\"text-align: justify;\">Being a recipient of orphan drug designation and breakthrough therapy designation, <strong>NiCord<\/strong> (under the late stage clinical development by Gamida Cell) holds a bright chance to emerge as an efficient therapy for HSCT. Products from other companies such as <a href=\"https:\/\/nohlatherapeutics.com\/\">Nohla Therapeutics<\/a>, ExcellThera and others are under the phase II developmental studies. <strong>NLA101<\/strong> being developed by Nohla Therapeutics in phase II stages provides a stiff competition to NiCord after receiving an orphan drug designation by the European Commission.<\/p>\n<p style=\"text-align: justify;\">Also, a number of non-transplant therapies are under development for the prophylaxis of GvHD and other complications associated with HSCT.<\/p>\n<p style=\"text-align: justify;\"><strong><em>Vidhi Khosla<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Associate Analyst<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hematopoietic stem cells (HSCs)\u00a0are characterized by the ability to self-renew and differentiate into all mature blood lineages. Stromal interactions with soluble and cell-bound cytokines structures the differentiations and proliferation of hematopoietic cells. Hematopoietic stem cell transplantation (HSCT) is the intravenous infusion of hematopoietic stem and progenitor cells intended to establish marrow and immune function in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2730,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1118,1627,204,17623,6601,1624,1625,381,1629,1630,17622,1626,1261,706],"industry":[17225],"therapeutic_areas":[17235,17238,17228,17234],"class_list":["post-2641","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-business-research","tag-chemotherapy-resistant-hematological-malignancies","tag-delveinsight","tag-excellthera","tag-graft-versus-host-disease-4","tag-hematopoietic-stem-cells-hscs","tag-intravenous-infusion","tag-market-research","tag-nicord","tag-nla101","tag-nohla-therapeutics","tag-peripheral-blood","tag-pharma-consulting","tag-pharmaceutical-industry","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Hematopoietic Stem Cells (HSC) Transplantation- Delveinsight<\/title>\n<meta name=\"description\" content=\"Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hematopoietic Stem Cells (HSC) Transplantation- Delveinsight\" \/>\n<meta property=\"og:description\" content=\"Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-11T12:06:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-17T05:25:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/09021721\/538948_Hematopoietic_Stem_Cell_Transplantation_-_Pipeline_Insight_2018.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"565\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hematopoietic Stem Cells (HSC) Transplantation- Delveinsight","description":"Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation","og_locale":"en_US","og_type":"article","og_title":"Hematopoietic Stem Cells (HSC) Transplantation- Delveinsight","og_description":"Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages.","og_url":"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-05-11T12:06:16+00:00","article_modified_time":"2023-08-17T05:25:50+00:00","og_image":[{"width":400,"height":565,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/09021721\/538948_Hematopoietic_Stem_Cell_Transplantation_-_Pipeline_Insight_2018.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation","url":"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation","name":"Hematopoietic Stem Cells (HSC) Transplantation- Delveinsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/09021721\/538948_Hematopoietic_Stem_Cell_Transplantation_-_Pipeline_Insight_2018.jpg","datePublished":"2018-05-11T12:06:16+00:00","dateModified":"2023-08-17T05:25:50+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and differentiate into all mature blood lineages.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/09021721\/538948_Hematopoietic_Stem_Cell_Transplantation_-_Pipeline_Insight_2018.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/09021721\/538948_Hematopoietic_Stem_Cell_Transplantation_-_Pipeline_Insight_2018.jpg","width":400,"height":565,"caption":"Hematopoietic stem cells"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/05\/09021721\/538948_Hematopoietic_Stem_Cell_Transplantation_-_Pipeline_Insight_2018-212x300.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">chemotherapy-resistant hematological malignancies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ExcellThera<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Graft versus host disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hematopoietic stem cells (HSCs)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">intravenous infusion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NiCord<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NLA101<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Nohla Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Peripheral Blood<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">chemotherapy-resistant hematological malignancies<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">ExcellThera<\/span>","<span class=\"advgb-post-tax-term\">Graft versus host disease<\/span>","<span class=\"advgb-post-tax-term\">Hematopoietic stem cells (HSCs)<\/span>","<span class=\"advgb-post-tax-term\">intravenous infusion<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">NiCord<\/span>","<span class=\"advgb-post-tax-term\">NLA101<\/span>","<span class=\"advgb-post-tax-term\">Nohla Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Peripheral Blood<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on May 11, 2018","modified":"Updated on Aug 17, 2023"},"absolute_dates_time":{"created":"Posted on May 11, 2018 5:36 pm","modified":"Updated on Aug 17, 2023 10:55 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2641"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2641\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2730"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2641"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2641"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2641"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2641"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}